Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Debt: 2020-2024

Historic Non-Current Debt for Syndax Pharmaceuticals (SNDX) over the last 2 years, with Dec 2024 value amounting to $331.6 million.

  • Syndax Pharmaceuticals' Non-Current Debt was N/A to $331.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $331.6 million, marking a year-over-year change of. This contributed to the annual value of $331.6 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, Syndax Pharmaceuticals' Non-Current Debt stood at $331.6 million, which was up 2,451.68% from $13.0 million recorded in Q2 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Non-Current Debt peaked at $331.6 million during Q4 2024, and registered a low of $11.0 million during Q3 2021.
  • In the last 2 years, Syndax Pharmaceuticals' Non-Current Debt had a median value of $16.5 million in 2022 and averaged $120.3 million.
  • Examining YoY changes over the last 5 years, Syndax Pharmaceuticals' Non-Current Debt showed a top increase of 11.56% in 2021 and a maximum decrease of 45.07% in 2021.
  • Over the past 4 years, Syndax Pharmaceuticals' Non-Current Debt (Quarterly) stood at $17.8 million in 2020, then climbed by 11.56% to $19.9 million in 2021, then declined by 2.47% to $13.0 million in 2022, then reached $331.6 million in 2024.
  • Its last three reported values are $331.6 million in Q4 2024, $13.0 million for Q2 2022, and $16.5 million during Q1 2022.